Maharashtra FDA Cancels 10 Ayurvedic Drug Licences Over Quality Violations
Source: ET Real Estate
The Maharashtra Food and Drug Administration (FDA) has cancelled the manufacturing licenses of ten Ayurvedic drug makers following a statewide crackdown. Inspections revealed serious violations of quality control and manufacturing standards, with 135 other manufacturers receiving show-cause notices for non-compliance.
- ▸The Maharashtra FDA has cancelled manufacturing licenses for 10 Ayurvedic drug makers.
- ▸This is part of a statewide crackdown revealing serious quality control and manufacturing violations.
- ▸Another 135 manufacturers have received show-cause notices for non-compliance issues.
- ▸The FDA aims to ensure Ayurvedic medicines meet required standards and protect public health.
- ✓The Maharashtra FDA has cancelled manufacturing licenses for 10 Ayurvedic drug makers.
- ✓This is part of a statewide crackdown revealing serious quality control and manufacturing violations.
- ✓Another 135 manufacturers have received show-cause notices for non-compliance issues.
- ✓The FDA aims to ensure Ayurvedic medicines meet required standards and protect public health.
The Maharashtra Food and Drug Administration (FDA) has taken stringent action against Ayurvedic drug manufacturers in the state, permanently cancelling the licenses of ten firms. This move comes after a comprehensive statewide crackdown that uncovered serious violations of manufacturing and quality control standards across numerous establishments.
During the extensive inspections, FDA officials identified widespread non-compliance issues within the Ayurvedic drug manufacturing sector. Following these findings, a total of 135 manufacturers were issued show-cause notices, demanding explanations for their failure to adhere to prescribed standards. The most severe actions, leading to license cancellations, were reserved for ten manufacturers whose major violations were deemed to directly impact public health.
Statewide Crackdown Details
The crackdown aimed to ensure that all Ayurvedic medicines produced and sold in Maharashtra meet the required quality and safety standards. The inspections specifically focused on aspects such as raw material procurement, manufacturing processes, hygiene, labeling, and adherence to Good Manufacturing Practices (GMP). The serious lapses found at the ten establishments led to their permanent closure, underscoring the FDA's commitment to consumer safety.
The issuance of show-cause notices to 135 other manufacturers indicates a broader effort to bring the entire industry into compliance. These notices typically require companies to explain the identified non-compliance issues and outline corrective actions they plan to take. Failure to provide satisfactory responses or implement necessary changes could lead to further penalties, including suspensions or cancellations of their licenses.
Ensuring Public Health and Quality
This regulatory action by the Maharashtra FDA is a significant step towards safeguarding the health of consumers who rely on Ayurvedic medicines. Ayurvedic products are widely used across India, and ensuring their quality, safety, and efficacy is paramount. The FDA stated that its ongoing efforts are dedicated to addressing public health lapses and upholding the integrity of the traditional medicine system.
Consumers are advised to remain vigilant and purchase Ayurvedic products only from reputable sources, ensuring they are properly packaged and labelled. The FDA's continued scrutiny aims to build trust in the Ayurvedic sector by enforcing strict quality control measures, thereby protecting public health from substandard or unsafe products.
This report is for informational purposes only and does not constitute medical or purchasing advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What action has the Maharashtra FDA taken recently?
The Maharashtra FDA has permanently cancelled the manufacturing licenses of ten Ayurvedic drug manufacturers and issued show-cause notices to 135 others as part of a statewide crackdown.
Why were these actions taken against Ayurvedic drug manufacturers?
Actions were taken due to serious violations of manufacturing and quality control standards found during inspections, with the cancelled licenses specifically linked to major violations affecting public health.
How many companies were affected by the FDA's crackdown?
A total of 145 companies were affected; ten had their licenses permanently cancelled, and 135 others received show-cause notices for non-compliance.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.
Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
Related Stories
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.
Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.